Patents Assigned to Sun Pharmaceutical Industries Ltd.
-
Patent number: 11554207Abstract: A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.Type: GrantFiled: February 9, 2017Date of Patent: January 17, 2023Assignee: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Subhas Balaram Bhowmick, Prashant Kane, Samarth Kumar, Kirti Ganorkar
-
Publication number: 20220265644Abstract: A composition for treating malaria comprising Arterolane and Piperaquine is disclosed. The Arterolane and Piperaquine are present in an effective amount according a body-weight dosing regimen of a patient.Type: ApplicationFiled: May 11, 2022Publication date: August 25, 2022Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Altaf LAL, Amit NASA
-
Patent number: 11058679Abstract: The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherein the aqueous solution is stable at room temperature.Type: GrantFiled: August 1, 2016Date of Patent: July 13, 2021Assignee: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Subhas Balaram Bhowmick, Prashant Kane, Samarth Kumar, Ramaji Karshanbhai Varu, Nisarg Bipinchandra Mistry, Swapnil Ramesh Patil
-
Patent number: 10869867Abstract: The present invention relates to an intravenous infusion dosage form of pemetrexed or its pharmaceutically acceptable salt, having long term stability.Type: GrantFiled: February 12, 2016Date of Patent: December 22, 2020Assignee: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Samarth Kumar, Prashant Kane, Subhas Balaram Bhowmick, Kirti Ganorkar, Nisarg Bipinchandra Mistry, Ramaji Karshanbhai Varu
-
Publication number: 20200360598Abstract: A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.Type: ApplicationFiled: February 9, 2017Publication date: November 19, 2020Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Subhas Balaram BHOWMICK, Prashant KANE, Samarth KUMAR, Kirti GANORKAR
-
Publication number: 20200163962Abstract: A method of treating leukaemia comprising orally administering to a patient in need thereof reduced daily doses of nilotinib of 100 mg to 600 mg, wherein the nilotinib is administered in a dosage form having a composition comprising nilotinib butanedisulphonate (2:1) or nilotinib butanedisulphonate (1:1).Type: ApplicationFiled: March 17, 2017Publication date: May 28, 2020Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Harshal JAHAGIRDAR, Bhushan JADHAV, Amol KULKARNI, Shirish KULKARNI, Rajamannar THENNATI
-
Patent number: 10285908Abstract: The present invention relates to a dual-chamber pack for a multi-dose oral liquid pharmaceutical composition wherein the compositions of the first and second chambers are mixed at the time of first administration.Type: GrantFiled: July 30, 2015Date of Patent: May 14, 2019Assignee: Sun Pharmaceutical Industries LtdInventors: Bhupesh Kumar Mittal, Neha Pardal
-
Patent number: 10272131Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.Type: GrantFiled: August 11, 2015Date of Patent: April 30, 2019Assignee: Sun Pharmaceutical Industries Ltd.Inventors: Rajamannar Thennati, Shirish Kulkarni, Sanjay Poptani, Vimal Kaneria, T. Nathamani
-
Publication number: 20190105262Abstract: The present invention relates to an intravenous infusion dosage form comprising: an aqueous solution of pemetrexed or its pharmaceutically acceptable salt at a concentration ranging from 1.0 mg/ml to 20.0 mg/ml present in a multilayered flexible plastic infusion container, wherein the multilayered flexible plastic infusion container has an oxygen scavenger layer sandwiched between an outermost and an innermost layer of the container, the container being free of a polyamide and wherein the multilayered flexible plastic infusion container filled with the aqueous solution of pemetrexed is autoclavable.Type: ApplicationFiled: October 10, 2018Publication date: April 11, 2019Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Samarth KUMAR, Ramaji Karshanbhai VARU, Nishit PATEL, Prashant KANE, Subhas Balaram BHOWMICK
-
Publication number: 20190008847Abstract: The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherein the aqueous solution is stable at room temperature.Type: ApplicationFiled: August 1, 2016Publication date: January 10, 2019Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Subhas Balaram BHOWMICK, Prashant KANE, Samarth KUMAR, Ramaji Karshanbhai VARU, Nisarg Bipinchandra MISTRY, Swapnil Ramesh PATIL
-
Patent number: 10172802Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.Type: GrantFiled: June 19, 2017Date of Patent: January 8, 2019Assignee: Sun Pharmaceutical Industries Ltd.Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
-
Patent number: 10092522Abstract: The present invention relates to a capsule composition of raloxifene comprising multiparticulates, comprising a) a core comprising raloxifene; and b) a taste-masking coating present in an amount of from about 15% to about 80% w/w based on the total weight of the composition.Type: GrantFiled: December 12, 2017Date of Patent: October 9, 2018Assignee: Sun Pharmaceutical Industries, Ltd.Inventors: Ujjwal Ranjan, Mona Dhaliwal, Mukesh K. Garg
-
Patent number: 10016391Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.Type: GrantFiled: November 7, 2017Date of Patent: July 10, 2018Assignee: Sun Pharmaceutical Industries, Ltd.Inventors: Ravindra Agarwal, Tarun Singhal, Ravi Kochhar
-
Publication number: 20180147238Abstract: The present invention relates to composition of iron sucrose and process for its preparation. The present invention also related to a process for the preparation of iron sucrose suitable for the iron sucrose composition.Type: ApplicationFiled: May 27, 2016Publication date: May 31, 2018Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Rajamannar THENNATI, Shriprakash Dhar DWIVEDI, V S N Murty KADIYALA, V, Kanaksinh Jesingbhai JADAV, Bharat Avcharbhai KAILA, Keyur Shashikant THAKER, Binaka Rahul DOLE
-
Publication number: 20180064703Abstract: The present invention relates to an infusion dosage form comprising (i) an aqueous solution of morphine or its pharmaceutically acceptable salt as a sole active ingredient in a concentration ranging from about 0.1 mg/ml to about 10.0 mg/ml, filled in containers in volumes ranging from about 50 ml to about 250 ml, and having dissolved oxygen content of less than 2 ppm, (ii) the container being surrounded by an outer covering, and (iii) an inert gas or vacuum is present in the space between the container and outer covering, wherein the infusion dosage form is sterilized by autoclaving and is stable upon autoclaving, and further wherein the space between the container and outer covering does not have an oxygen scavenger pouch before or during autoclaving.Type: ApplicationFiled: September 1, 2017Publication date: March 8, 2018Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Samarth KUMAR, Prashant KANE, Subhas Balaram BHOWMICK, Milan Natvarbhai THAKKAR, Kandarp Maheshkumar DAVE
-
Publication number: 20180036310Abstract: The present invention relates to an intravenous infusion dosage form of pemetrexed or its pharmaceutically acceptable salt, having long term stability.Type: ApplicationFiled: February 12, 2016Publication date: February 8, 2018Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Samarth KUMAR, Prashant KANE, Subhas Balaram BHOWMICK, Kirti GANORKAR, Nisarg Bipinchandra MISTRY, Ramaji Karshanbhai VARU
-
Publication number: 20170340579Abstract: A transdermal delivery system comprising a drug-containing matrix layer, a release liner and a backing layer. The drug-containing matrix layer further comprises a methylphenidate base, an adhesive polymer made up of a styrene rubber block copolymer having a styrene content of 24% or above by weight of the adhesive polymer; the adhesive polymer is present in an amount of 20% to 45% by weight of the drug-containing matrix layer, a tackifier present in an amount of 30% to 45% by weight of the drug-containing matrix layer, and a hydrocarbon plasticizer present in an amount of 1% to 30% by weight of the drug-containing matrix layer.Type: ApplicationFiled: May 26, 2017Publication date: November 30, 2017Applicant: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Madhusudhan BOMMAGANI, Pijush Kanti MIDYA, Krunal RAVAL, Subhas Balaram BHOWMICK, Prashant KANE
-
Publication number: 20170281556Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.Type: ApplicationFiled: June 19, 2017Publication date: October 5, 2017Applicant: Sun Pharmaceutical Industries Ltd.Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
-
Publication number: 20170273923Abstract: A compact sustained release tablet comprising divalproex or its pharmaceutically acceptable salts as a sole active ingredient is present in an amount equivalent to from about 700 mg to about 1500 mg of valproic acid and pharmaceutically acceptable tablet excipients; wherein weight ratio of pharmaceutically acceptable tablet excipients to divalproex and/or its salt is less than 1, the tablet is suitable for once a day administration and when orally administered, with or without food, the ratio of mean AUC0_inf-fasted to mean AUC0_inf-fed is within the range of 0.9 to 1.1.Type: ApplicationFiled: March 23, 2017Publication date: September 28, 2017Applicant: Sun Pharmaceutical Industries Ltd.Inventors: Vishal Suhagiya, T. Nathamani, Amol Kulkarni, Shirish Kulkarni, Rajamannar Thennati
-
Publication number: 20170232058Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.Type: ApplicationFiled: August 11, 2015Publication date: August 17, 2017Applicant: Sun Pharmaceutical Industries Ltd.Inventors: Rajamannar Thennati, Shirish Kulkarni, Sanjay Poptani, Vimal Kaneria, T. Nathamani